A Phase I Study to Assess the Tolerability, Safety and Biological Effects of ATR Inhibitor (AZD6738) as a Single Agent and in Combination With Palliative Radiation Therapy in Patients With Solid Tumours

Trial Profile

A Phase I Study to Assess the Tolerability, Safety and Biological Effects of ATR Inhibitor (AZD6738) as a Single Agent and in Combination With Palliative Radiation Therapy in Patients With Solid Tumours

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs AZD 6738 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Acronyms PATRIOT
  • Most Recent Events

    • 05 Apr 2017 Early results of the monotherapy dose-escalation phase (part A, n=26), presented at the 108th Annual Meeting of the American Association for Cancer Research.
    • 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 05 Oct 2015 Accrual to date is 10% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top